Active ingredientEtrasimodCat. No. P-E141-001CAS 1206123-37-6Family · Pharmaceutical analytical standards
Etrasimod
An oral sphingosine-1-phosphate (S1P) receptor modulator that keeps some activated lymphocytes away from inflamed tissue; approved in the United States in 2023 for ulcerative colitis in adults. This family brings together the active ingredient, labelled standards, nitrosamines and other impurities.
Did you know?It is selective: it binds S1P receptor subtypes 1, 4 and 5 while avoiding subtypes 2 and 3. It has also been studied for Crohn's disease, atopic dermatitis and alopecia areata.
Go to the active ingredient →Active ingredientEtrasimodCat. No. P-E141-001CAS 1206123-37-6
Isotopically labelledrac-Etrasimod-d9Cat. No. P-E141-003
NitrosamineN-Nitroso EtrasimodCat. No. P-E141-004
ImpurityEtrasimod Impurity 1Cat. No. P-E141-005CAS 957208-65-0
ImpurityEtrasimod Impurity 2Cat. No. P-E141-006CAS 957205-39-9
ImpurityEtrasimod IntermediatesCat. No. P-E141-007CAS 1206124-13-1
ImpurityEtrasimod Impurity 3Cat. No. P-E141-008CAS 115591-64-5
ImpurityEtrasimod Impurity 4Cat. No. P-E141-009CAS 161622-16-8
Impurityrac-EtrasimodCat. No. P-E141-010CAS 1206123-55-8No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.